Medicare Enrolled
Dr. Hakan Kaya, M.D.
Medical Oncology · Spokane, WA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kaya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kaya?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kaya
Dr. Hakan Kaya is a medical oncology specialist in Spokane, WA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kaya performed 66,039 Medicare services across 2,708 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kaya received a total of $2,128,302 from 46 pharmaceutical and/or device companies across 1496 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kaya is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 8% volume in WA
$2,128,302 industry payments
Medicare Practice Summary
Medicare Utilization ↗66,039
Medicare services
Top 8% in WA for medical oncology
2,708
Unique beneficiaries
$27
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,302 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
35,640 | $36 | $111 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
6,720 | $0 | $3 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
4,515 | $4 | $115 |
| Denosumab injection (Prolia/Xgeva) | 4,500 | $18 | $52 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,524 | $0 | $1 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
2,890 | $21 | $181 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,295 | $7 | $40 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,260 | $8 | $12 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
635 | $131 | $359 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
552 | $12 | $74 |
| Injection, granisetron hydrochloride, 100 mcg | 510 | $0 | $11 |
| Anti-nausea injection (Aloxi/palonosetron) | 510 | $1 | $114 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
360 | $89 | $266 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
356 | $57 | $250 |
| Rasburicase injection, 0.5 mg Administration of a 0.5 mg dose of rasburicase via injection. |
339 | $278 | $805 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
321 | $6 | $135 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
253 | $105 | $472 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
221 | $66 | $177 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
177 | $11 | $71 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
161 | $0 | $2 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
158 | $23 | $105 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
151 | $1 | $10 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
95 | $52 | $232 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
92 | $49 | $225 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
75 | $58 | $525 |
| Sedation by physician, initial 15 minutes Administration of a drug to induce depression of consciousness by the physician performing a procedure. This code covers the initial 15 minutes of sedation for patients aged 5 years or older. |
69 | $9 | $157 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
69 | $92 | $269 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
68 | $96 | $346 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
62 | $10 | $53 |
| New patient office visit, complex (60-74 min) | 50 | $170 | $513 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
43 | $53 | $803 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
41 | $20 | $88 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
39 | $175 | $900 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
38 | $16 | $69 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
36 | $6 | $32 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
35 | $23 | $111 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
28 | $30 | $169 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
28 | $136 | $509 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
23 | $3 | $12 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
23 | $27 | $120 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
23 | $2 | $34 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
22 | $38 | $110 |
| Bone density scan (DEXA) A test that uses low-dose X-rays to measure bone mineral density in the hip, pelvis, and spine. It helps assess bone strength and risk of fractures. |
21 | $29 | $212 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
11 | $24 | $176 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.8% high complexity
92.5% medium
6.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,128,302
Total received (2018-2024)
Avg $304,043/year across 7 years
Top 1% in WA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
1,496
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,089,809 (98.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$36,161 (1.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,333 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$420,032
2023
$319,762
2022
$359,272
2021
$310,612
2020
$242,763
2019
$229,005
2018
$246,857
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Takeda Pharmaceuticals U.S.A., Inc.
$79,128
BeiGene USA, Inc.
$74,367
PFIZER INC.
$65,458
Karyopharm Therapeutics Inc.
$54,164
GENZYME CORPORATION
$44,291
GlaxoSmithKline, LLC.
$40,036
ABBVIE INC.
$32,678
Genmab U.S., Inc.
$23,086
Amgen Inc.
$4,429
Janssen Biotech, Inc.
$1,377
E.R. Squibb & Sons, L.L.C.
$167
Incyte Corporation
$165
AstraZeneca Pharmaceuticals LP
$163
Novartis Pharmaceuticals Corporation
$134
Celgene Corporation
$58
Mirati Therapeutics, Inc.
$53
Merck Sharp & Dohme LLC
$49
Janssen Pharmaceuticals, Inc
$26
Daiichi Sankyo Inc.
$25
Lilly USA, LLC
$24
Blueprint Medicines Corporation
$24
Rigel Pharmaceuticals, Inc.
$23
ARRAY BIOPHARMA INC
$21
Adaptive Biotechnologies Corporation
$19
ADC Therapeutics America, Inc.
$19
Acrotech Biopharma Inc.
$17
Regeneron Healthcare Solutions, Inc.
$16
PUMA BIOTECHNOLOGY, INC.
$14
Top 3 companies account for 52.1% of 2024 payments
All-time payments by company (2018-2024) ›
Takeda Pharmaceuticals U.S.A., Inc.
$539,249
Karyopharm Therapeutics Inc.
$516,436
GlaxoSmithKline, LLC.
$201,118
BeiGene USA, Inc.
$161,833
E.R. Squibb & Sons, L.L.C.
$151,330
Amgen Inc.
$134,366
GENZYME CORPORATION
$123,714
PFIZER INC.
$65,536
Janssen Biotech, Inc.
$47,074
Celgene Corporation
$43,114
ABBVIE INC.
$32,678
Genmab U.S., Inc.
$23,086
Lilly USA, LLC
$18,059
Epizyme, Inc.,
$15,614
Kite Pharma, Inc.
$14,430
Janssen Scientific Affairs, LLC
$12,409
Seagen Inc.
$12,397
Teva Pharmaceuticals USA, Inc.
$5,466
Ipsen Biopharmaceuticals, Inc
$4,785
Incyte Corporation
$3,685
Pharmacyclics LLC, An AbbVie Company
$384
AstraZeneca Pharmaceuticals LP
$288
Seattle Genetics, Inc.
$240
Bayer HealthCare Pharmaceuticals Inc.
$187
Novartis Pharmaceuticals Corporation
$134
Merck Sharp & Dohme Corporation
$116
Boehringer Ingelheim Pharmaceuticals, Inc.
$91
Merck Sharp & Dohme LLC
$89
Mirati Therapeutics, Inc.
$53
AbbVie Inc.
$49
Janssen Pharmaceuticals, Inc
$26
Daiichi Sankyo Inc.
$25
Blueprint Medicines Corporation
$24
Rigel Pharmaceuticals, Inc.
$23
ARRAY BIOPHARMA INC
$21
Adaptive Biotechnologies Corporation
$19
ADC Therapeutics America, Inc.
$19
Dendreon Pharmaceuticals LLC
$19
Genentech USA, Inc.
$18
Acrotech Biopharma Inc.
$17
MorphoSys, US Inc.
$17
Regeneron Healthcare Solutions, Inc.
$16
PUMA BIOTECHNOLOGY, INC.
$14
Acrotech Biopharma LLC
$14
Gilead Sciences, Inc.
$12
Clovis Oncology, Inc.
$8
Top 3 companies account for 59.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · BB-2121 · BELEODAQ · BLENREP · BOSULIF · BRUKINSA · CALQUENCE · Columvi · DARZALEX · ELITEK · ELREXFIO · EMPLICITI · EPKINLY · ERLEADA · EXKIVITY · Epkinly · Fabhalta · GILOTRIF · ICLUSIG · IMBRUVICA · INJECTAFER · Imbruvica · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUTATHERA · MONJUVI · NINLARO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · PROVENGE · Pomalyst · REBLOZYL · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · TAZVERIK · TECVAYLI · Tazverik · VENCLEXTA · VERZENIO · XGEVA · XPOVIO · Xofigo · Yescarta · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (98%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for medical oncology in WA.
Geographic Context
Medical oncologists within 10 mi
10
Per 100K population
1.8
County median income
$73,513
Nearest hospital
SHRINERS HOSPITAL FOR CHILDREN
2.3 mi
2.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kaya is a mixed practice specialist, with above-average Medicare volume (top 8% in WA), with speaking/promotional industry engagement in the top 1% of WA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kaya experienced with daratumumab injection (darzalex)?
Based on Medicare claims data, Dr. Kaya performed 35,640 daratumumab injection (darzalex) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kaya receive payments from pharmaceutical companies?
Yes. Dr. Kaya received a total of $2,128,302 from 46 companies across 1,496 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kaya's costs compare to other medical oncologists in Spokane?
Dr. Kaya's average Medicare payment per service is $27. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kaya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Spokane
Browse medical oncologists in Spokane ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in WA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in WA
Which WA medical oncologists receive the most from drug and device companies.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Karyopharm Therapeutics Inc. Payments to Doctors
See all physicians who received payments from Karyopharm Therapeutics Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology